270 related articles for article (PubMed ID: 23615530)
1. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?
Okafor PN; Nunes DP; Farraye FA
Inflamm Bowel Dis; 2013 Jul; 19(8):1764-71. PubMed ID: 23615530
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers.
Okafor PN; Wasan SK; Farraye FA
Inflamm Bowel Dis; 2013; 19(4):812-7. PubMed ID: 23435401
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
Sierra CM; Daiya KC
Pharmacotherapy; 2022 Nov; 42(11):858-867. PubMed ID: 36222368
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors of Pneumocystis jirovecii pneumonia in Korean patients with inflammatory bowel disease.
Nam K; Park SH; Lee J; Jo S; Kim SO; Noh S; Park JC; Kim JY; Kim J; Ham NS; Oh EH; Song EM; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK
J Gastroenterol Hepatol; 2020 Feb; 35(2):218-224. PubMed ID: 31412420
[TBL] [Abstract][Full Text] [Related]
6. Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review.
Grewal P; Brassard A
J Cutan Med Surg; 2009; 13(6):308-12. PubMed ID: 19919808
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
8. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK; Foisy MM; Hughes CA
Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.
Okafor PN; Farraye FA; Okafor AT; Erim DO
Dig Dis Sci; 2015 Dec; 60(12):3743-55. PubMed ID: 26177704
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
13. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
14. Using Routine Laboratory Markers and Immunological Indicators for Predicting
Tang G; Tong S; Yuan X; Lin Q; Luo Y; Song H; Liu W; Wu S; Mao L; Liu W; Zhu Y; Sun Z; Wang F
Front Immunol; 2021; 12():652383. PubMed ID: 33912176
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
[TBL] [Abstract][Full Text] [Related]
16. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study.
Chan SCW; Chung HY; Lau CS; Li PH
Ann Clin Microbiol Antimicrob; 2021 Nov; 20(1):78. PubMed ID: 34763703
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease-a Case Series.
Vieujean S; Moens A; Hassid D; Rothfuss K; Savarino EV; Vavricka SR; Reenaers C; Jacobsen BA; Allez M; Ferrante M; Rahier JF
J Crohns Colitis; 2023 Apr; 17(4):472-479. PubMed ID: 36223253
[TBL] [Abstract][Full Text] [Related]
19. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Features of Pneumocystis Jiroveci Pneumonia in Patients with Inflammatory Bowel Disease].
Meng XC; Li J; Wu D; Xu H; Dong XY; Han HQ; Wu DS; Qian JM; Li JN
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Aug; 40(4):450-455. PubMed ID: 30193596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
